There is growing evidence that the coronavirus may be able to re-infect patients, and a new instance of a second infection has been confirmed in the US.
Ayming Group’s second annual International Innovation Barometer (IIB) has said that the international outlook for R&D is “remarkably promising” despite strong headwinds caused by COVID-
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange.
The spotlight remains on the potential of antibody therapies as a possible way out of the COVID-19 pandemic crisis, with the US government investing millions in a hopeful from AstraZeneca a
Gastroenterologist Dr Séverine Vermeire explains how lockdowns and communication changes over COVID-19 are taking their toll on ulcerative colitis patients and how we can best support them
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.